The current status of the Stanford randomized clinical trials of the management of Hodgkin’s disease

1985 ◽  
pp. 281-292 ◽  
Author(s):  
S. A. Rosenberg
Keyword(s):  
Clinical Trials ◽  
Hodgkin's Disease ◽  
Randomized Clinical Trials ◽  
Hodgkin’S Disease ◽  
Current Status

Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD

1997 ◽  
Vol 15 (7) ◽  
pp. 2762-2762 ◽  
Author(s):  
Joseph M. Connors ◽  
Paul Klimo ◽  
Grenfell Adams ◽  
Bruce F. Burns ◽  
Ian Cooper ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clin Oncol ◽  
National Cancer Institute ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Cancer Centre ◽  
Regional Cancer Centre ◽  
Advanced Hodgkin’S Disease

The institution affiliation section on page 1638 of the April 1997 article entitled, "Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD: A Report From the National Cancer Institute of Canada Clinical Trials Group" by Connors, et al (J Clin Oncol 15:1638–1645, 1997) was incomplete. The "London Regional Cancer Centre, London, Ontario, Canada" should have been included in the listing of author-affiliated institutions.

Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis

2001 ◽  
Vol 19 (7) ◽  
pp. 2026-2032 ◽  
Author(s):  
Ulrich Rueffer ◽  
Andreas Josting ◽  
Jeremy Franklin ◽  
Michael May ◽  
Markus Sieber ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Disease Free Survival ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Lymphoma Study Group ◽  
First Diagnosis

PURPOSE: The cumulative incidence for non-Hodgkin lymphoma’s (NHL) after primary Hodgkin’s disease (HD) ranges between 1% and 6%. To investigate the course of disease for secondary NHL, we retrospectively analyzed patients treated within clinical trials of the German Hodgkin’s Lymphoma Study Group (GHSG) since 1981. PATIENTS AND METHODS: From 1981 to 1998, the GHSG conducted three generations of clinical trials for the treatment of primary HD involving a total of 5,406 patients. Reference histology by an expert panel was obtained for 4,104 of the patients. Data on incidence, treatment, and outcome of secondary NHL were updated in March 1999. RESULTS: At first diagnosis of HD, the pathologists rejected 114 (2.1%) of 5,520 cases initially diagnosed as HD and rediagnosed them as primary NHL. Fifty-two (0.9%) of the remaining 5,406 patients developed a secondary NHL. One patient was excluded from further analyses because of insufficient documentation. Six patients had no further therapy because of patient refusal (n = 1) or rapidly progressive disease (n = 5). For the remaining 45 patients, overall response rate was 43% (36% complete response and 7% partial response). The actuarial 2-year freedom from treatment failure (FFTF) and overall survival (OS) for all patients was 24% and 30%, respectively, and for patients with diffuse large-cell lymphoma, it was 28% and 35%, respectively. Time of occurrence of secondary NHL after first diagnosis of HD and variables employed in the age-adjusted International Prognostic Factor Index (IPFI) significantly influenced treatment outcome. CONCLUSION: In the GHSG, the incidence of secondary NHL with 0.9% is relatively low compared with previously reported series. The prognosis of secondary NHL seems dismal and is significantly influenced by time of occurrence and the age-adjusted IPFI. In a subset of patients with secondary NHL, long-term disease-free survival could be achieved.

scholarly journals Current clinical trials in Hodgkin's disease

1996 ◽  
Vol 7 ◽  
pp. S109-S113 ◽  
Author(s):  
K. Reuß ◽  
A. Engert ◽  
H. Tesch ◽  
V. Diehl
Keyword(s):  
Clinical Trials ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease

Current status of targeted agents (TA) in advanced pancreatic cancer (APC): Meta-analysis of randomized clinical trials (RCT)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4637-4637 ◽  
Author(s):  
M. Milella ◽  
E. Bria ◽  
F. Cuppone ◽  
A. J. Gelibter ◽  
C. Nuzzo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Advanced Pancreatic Cancer ◽  
Current Status ◽  
Targeted Agents

scholarly journals Therapy of Mucormycosis

2018 ◽  
Vol 4 (3) ◽  
pp. 90 ◽  
Author(s):  
Nikolaos V. Sipsas ◽  
Maria N. Gamaletsou ◽  
Amalia Anastasopoulou ◽  
Dimitrios P. Kontoyiannis
Keyword(s):  
Clinical Trials ◽  
Amphotericin B ◽  
Opportunistic Infection ◽  
Randomized Clinical Trials ◽  
Treatment Options ◽  
Management Plan ◽  
Current Status ◽  
Pharmacological Properties ◽  
Different Types ◽  
Individualized Management

Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.

Sign in / Sign up

Export Citation Format

Share Document